SS1 through SS4, the numbers tell a consistent story. In T2.E new-energy production, Pau Navarro and Jan Rosa took the overall win in a GWM TANK 700 Hi4-T, with teammates Nicolás Cavigliasso and Valentina Pertegarini finishing second, and Gerard Farres and Bruno Jacomy in third — all three podium spots on the same model. In T2.1 fuel production, Eniriltu and Aobulege claimed the title with Nayintai and Onchinjab close behind. In T2.3 club production, Zhou Renbin and Zhang Tengzhong took the win, Huang Dongxu and Tang Shixin came in second, and Zhang Guoqiang and Lou Liyuan rounded out the podium. Across three groups, three GWM podiums, four stages, and twelve driver-navigator pairs with zero retirements.

The Taklimakan doesn’t care what big words you say. Nights bring bone-chilling cold, the midday sun blazes with unrelenting intensity, and one moment of slackening means being swallowed whole by the unforgiving soft sand.

SS3 was 468 kilometers — the longest special stage the rally has seen in years. SS2 cuts through the Kumtag Desert for 293 kilometers. Engine temperatures spike fast out there, and there’s almost no room for error.

GWM ran all four stages without a single mechanical retirement. That’s not luck. You put a vehicle in the desert, on its own terms — this is what you get.

The GWM TANK 700 Hi4-T in T2.E competition runs on the same powertrain as the vehicle that leaves the factory — the 3.0T V6 engine, Hi4-T hybrid system, transmission and four-wheel-drive architecture are unchanged. The vehicle was prepared to T2.E homologation requirements: safety equipment was installed to regulation standard, but nothing was modified in how the engine and hybrid system deliver power to the wheels. That means every kilometer driven in the rally is a real-world test of the production platform under extreme conditions. What the desert breaks, the Hi4-T system holds.

A production SUV goes four straight stages in the Taklimakan without breaking down. That’s not just a rally stat — it means something. The Hi4-T platform’s torque delivery, power management, heat tolerance — they all get pushed way harder than any road car ever would. Every part that makes it through the desert has been run past its design limits in conditions most owners will never see.

That’s what you actually get from motorsport-backed engineering. Not a car that’s quicker on paper. One that just doesn’t quit when things get ugly.

GWM ran the rally with four manufacturer teams, twelve driver-navigator pairs — Chinese and international — and a 5,000-square-meter dedicated camp outside Korla. The crew worked around the clock: cars went out, cars came back, the team prepared them for the next stage. Pau Navarro chose the GWM TANK 700 Hi4-T after testing it in Xinjiang before the rally. Gerard Farres made the same call independently. Dakar veterans do not pick a vehicle for the badge. They pick what the desert tells them works.

The rally continues. GWM leads in every category it entered.

Contact:globalmarketing@gwm.cn

The Company confirms that it continues to work diligently and cooperatively with both the British Columbia Securities Commission (“BCSC”) and the TSXV in connection with the FFCTO revocation process and the Company’s application for reinstatement of trading.

Fobi further announces that it has completed its Q3 2026 interim financial statements, related management’s discussion and analysis, and associated certifications (“Q3 Filings”). In an effort to ensure full compliance with applicable securities laws, accounting standards, and regulatory policies, the Company is voluntarily submitting the Q3 Filings to the BCSC for pre-filing review prior to public dissemination.

Management believes that this proactive approach will assist in streamlining the review process with the applicable regulatory authorities and support the Company’s continued efforts toward achieving a full revocation of the FFCTO and the resumption of trading.

“We continue to work closely and constructively with both the BCSC and the TSXV throughout this process,” said Rob Anson, Chief Executive Officer of Fobi. “While the process has required significant time and coordination, management believes that taking a careful, transparent, and cooperative approach is in the best interests of the Company and its shareholders. Submitting the Q3 Filings for pre-filing review reflects our commitment to ensuring full regulatory compliance and helping facilitate an efficient review process.”

The Company will continue to provide shareholders with material updates as they become available.

About Fobi AI

Fobi AI Inc. is a cutting-edge AI and data intelligence company that helps businesses digitally transform and future proof their organizations through AI driven analytics, digital wallet engagement, and real time customer activation solutions. Fobi works with some of the world’s leading organizations across retail, sports and entertainment, hospitality, telecom, and regulated industries to deliver next generation customer engagement and operational intelligence solutions.

On behalf of the Board of Directors
Fobi AI Inc.

Rob Anson
Chief Executive Officer and Director
rob@fobi.ai
604 256 6990

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements/Information:

This news release contains certain statements which constitute forward-looking statements or information, including statements regarding the receipt and timing of the revocation of the FFCTO and the resumption of trade of the Company’s shares on the TSXV, the receipt of all necessary approvals in connection with same, and other statements characterized by words such as “anticipates,” “may,” “can,” “plans,” “believes,” “estimates,” “expects,” “projects,” “targets,” “intends,” “likely,” “will,” “should,” “to be”, “potential” and other similar words, or statements that certain events or conditions “may”, “should” or “will” occur. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond the Company’s control, including, without limitation, market competition, the impact of general economic and industry conditions, competition, stock market volatility, BCSC and TSXV approval conditions, the ability of the Company to satisfy such approval conditions of the BCSC and TSXV, and the ability to access sufficient capital from internal and external sources. Although the Company believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the nature of the conditions imposed by the BCSC and the TSXV with respect to the revocation of the FFCTO and resumption of trading of the Company’s shares on the TSXV, changes to volatile exchange rates, market conditions, market competition and other economic and market factors. This forward-looking information may be affected by risks and uncertainties in the business of the Company and market conditions. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future plans, operations, and results, levels of activity or achievements.

The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, the Company does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of the Company should be considered highly speculative. There can be no assurance that the Company will be able to achieve all or any of its proposed objectives.

Pakistan China Relationship

PM Shehbaz with PM Li Qiang

ISLAMABAD, May 30, 2026 (GLOBE NEWSWIRE) — The Ministry of Information and Broadcasting (MoIB) is responsible for promoting and managing the official narrative surrounding Prime Minister Shehbaz Sharif’s visit to China, which celebrates the 75th anniversary of diplomatic relations.

For most of the last decade, Pakistan-China engagement was defined in terms of highways, energy infrastructure, ports, and the broader CPEC-based infrastructure projects, all of which revolutionized Pakistan’s economy, enhanced connectivity, and solved long-drawn energy crises. However, the Islamabad-Beijing partnership today is transcending into something much wider and a great deal more strategic.

This change was abundantly clear in the recent visit to China by the Prime Minister. The meeting with the Chinese Premier, Li Qiang, attendance at the Pakistan-China Third B2B Investment Forum and meetings with China’s tech giants were evident symbols of this shift in the Pakistan-China cooperation away from the traditional economic cooperation toward the newer dimensions like technology, innovation, industry and strategic cooperation.

The atmosphere of the visit itself was meaningful. Pakistan and China were not just looking at the volume of trade or individual deals. Instead, they were discussing a convergence in vision and future-focused industries and development plans in an era of fast-changing technological and political global economy.

The PM during his talks with Premier Li Qiang in Beijing, stated that the Pakistan-China All-Weather Strategic Cooperative Partnership would continue to remain the centerpiece of Pakistan’s foreign policy. The two sides expressed happiness with the gradual progress in the relationship and assured each other of support on each other’s core issues. Although this is a standard boilerplate statement made at diplomatic negotiations, however the context of the visit itself suggests that the two sides are moving ahead with the relationship to a new plane.

That transition is evident in CPEC too. It has been evolving from a focus mainly on large-scale infrastructure and connectivity to a model that encompasses industrialization, modernization of agriculture, digitization, clean energy, science, and high technology cooperation. This trend itself mirrors the realities of global developments. In today’s world, economic power and influence do not solely rely on locations or routes of trade but on technology, innovation and digital connectivity.

It seems that the Pakistani leadership has taken notice of that too. Prime Minister Shehbaz Sharif stressed the necessity of bringing China’s 15 th Five-Year Plan into sync with Pakistan’s “Uraan Pakistan” development agenda in order to speed up the practical cooperation and long-term economic coordination between the two countries. It has become clear that the discourse from Islamabad is that it is an aspiring participant in Asia’s technological and industrial future rather than restricted to traditional economic models.

An obvious manifestation of that increasing cooperation was evident during the Prime Minister’s visit to the headquarters of the Alibaba Group in Hangzhou. Pakistani delegation was given a warm welcome by Chairman Joe Tsai where both sides saw the signing of number of strategic MOUs between Alibaba Group and Pakistani public/private sector institutions. The areas of cooperation are mainly the digitalization process, technological enhancement and developing further cooperation in emerging sectors.

Yet the importance of the meeting extended beyond business alone. Joe Tsai acknowledged Pakistan’s efforts toward regional and global peace and stability while also appreciating the government’s focus on technological innovation and creating an environment attractive for international investment. Such remarks reflected growing Chinese confidence in Pakistan’s direction and broader regional role.

As such, Alibaba’s activity in Pakistan should be contextualised not simply as an isolated corporate venture, but as an extension of a broader pattern. Pakistani institutions and businesses are beginning to consider China not merely as the source of investment in physical infrastructure, but as a partner for enduring economic and technological development.

This macro-level transformation was in evidence during the entire visit. Repeated conversations revolved around digital transformation, science, connectivity, industrial growth and new technologies. The youth in Pakistan, with an increasing digital economy and growing tech sector, will increasingly become vital to its future ties with China.

The momentum was again deepened at the Pakistan-China Third B2B Investment Forum. Prime Minister Shehbaz Sharif proudly proclaimed that 30 percent of the MOUs between the two nations had “already converted to formal agreements,” and that this was an unprecedented event. Most international investment forums are fraught with lofty declarations that never follow through. It seemed the priorities between Islamabad and Beijing remained constant: implementation, persistence, and results.

The symbolic aspect of the visit also counted. At the forum, Prime Minister Shehbaz Sharif remarked that Pak-China friendship is “deeper than the oceans and higher than the Himalayas,” but with the launching of the space program, the friendship was now “touching the skies.” While at any other time, such comments could easily be dismissed as nothing more than rhetoric, given recent circumstances, they pointed towards a relationship that has now entered sectors that would eventually define the future global economy.

Collaboration in space appears as one of the most direct illustrations. PM Shehbaz Sharif spoke of Pakistani astronauts’ selection to the China space station program as a demonstration of growing trust and cooperation in the strategic, high-technology areas. Collaboration in space is not just of scientific and technological interest but of symbolically great value: it is a show of trust, long-term perspective and readiness to work on extremely strategic, hi tech areas.

The same is true of discourse on artificial intelligence and emerging technologies. No nation will freely allow cooperation in strategic technology fields without genuine political trust. It seems that Pakistan and China are moving into a phase where they appear not only economically aligned but in how they perceive long term regional stability and development.

Of course, security remains a key element. The assurances given by Prime Minister Shehbaz Sharif regarding the safety and security of Chinese nationals and projects in Pakistan were still relevant, as a sustained economic partnership depends on confidence, stability, and continuity on both sides.

More broadly, the significance of the visit highlights where Pakistan is headed. For so long, the international dialogue with Pakistan was one of just security or economic crises and political instability. While all these remain present and accounted for, another narrative has been unfolding simultaneously.

Slowly but surely, Pakistan is moving towards its place in a globalized world of technology, connectivity, and economic partnerships. China’s constant faith in Pakistan provides more than just investment to Islamabad; it lends a sense of strategic credibility in a world which is becoming more fractured and unstable geostrategically.

The Pakistan-China relationship is not only about roads, ports and power plants anymore. Roads, ports, and power plants were and still are the basic building blocks of the relationship but it is clear that the collaboration is expanding into fields such as Artificial Intelligence, Digital Trade, Industrial modernization, clean energy, science and space technology.

That transition may ultimately define the next chapter of Pakistan-China relations. The first phase focused on building physical connectivity across regions. The next phase appears focused on building technological, industrial, and strategic connectivity for the future.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/60eb09f0-644c-4431-9994-42a8d520018a

https://www.globenewswire.com/NewsRoom/AttachmentNg/e6a16230-f821-4587-b375-c132f467ea9e 

CONTACT: Muhammad Subayyal +923477195027

HONG KONG, May 29, 2026 (GLOBE NEWSWIRE) — AUAU Technology today announced the official global launch of its all-in-one sports and fitness business solution, auau.io. Designed specifically to empower small-to-medium-sized gyms, yoga studios, Pilates centers, dance studios and all sports centers, the platform provides a plug-and-play SaaS ecosystem that liberates business owners from tedious administrative tasks, allowing them to focus entirely on training quality and brand expansion.

Entering the global market as a highly stabilized, market-proven system, the platform is already trusted by over 500 brands across Asia particularly in Hong Kong and Malaysia. The software’s robust architecture was developed by the Onebox Creative Group, a renowned digital agency with over a decade of experience providing enterprise-grade business consulting and global IT solutions.

As a comprehensive studio and sports centers management tool, auau.io seamlessly integrates automated online booking, payment integration, and advanced customer relationship management (CRM) into a single operational hub. To accommodate the demands of a global clientele, the newly launched global version fully supports multi-language interfaces, multi-currency settlements, and cross-time zone scheduling. Built entirely on cloud-based infrastructure, studio owners can manage their operations anytime, anywhere, via mobile or web browser, without incurring high hardware costs.

“Our mission is to define a new standard of success for the next generation of sports and fitness entrepreneurs,” said Ms. Peggy Lee and Mr. Ryo Chan, co-founders of AUAU Technology. “By automating online payments, reducing manual financial reconciliation, and providing real-time data on member retention, our platform acts as a digital operational partner.”

“I’m a woman who started with zero tech background. After working in a technology company, I saw how difficult it was for a studio owner, especially women, to run their sport and wellness business. So I built AUAU. The easiest all-in-one appointment software for studios. It’s simple, no IT knowledge needed, and designed to grow with the community and the entire industry,” said Ms. Peggy Lee.

Beyond basic administration, the software actively drives revenue. The system automatically generates comprehensive financial reports and incorporates powerful promotional features, including targeted WhatsApp marketing, to enhance member retention and secure new leads.

Fitness and sports center operators looking to streamline their operations are encouraged to experience the system trusted by over 500 Asian brands. To learn more about the software or to schedule a personalized demonstration, visit the official website at www.auau.io.

About AUAU Technology

AUAU Technology is a premier SaaS provider specializing in sports and fitness studio management software. Developed by the digital experts at Onebox Creative Group, auau.io offers an all-in-one studio, club, gym and sports center management tool featuring online booking, payment integration, HR Management and CRM capabilities. Currently empowering over 500 fitness, yoga, and Pilates studios across Asia particularly in Hong Kong and Malaysia, the company provides plug-and-play, cloud-based operational solutions designed to help global sports and wellness entrepreneurs automate administration and scale their businesses.

Media Contact

Ryo Chan
Managing Director, AUAU Technology

Phone: +852 98005891, +60 12838 3162

Email: ryo.chan@auau.io
Website: www.auau.io

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b9225364-79dc-4595-95a0-10a7e3be7ab1

Tarrytown, New York, May 29, 2026 (GLOBE NEWSWIRE) — ENT & Allergy Associates, the nation’s largest ENT and Allergy practice, today announced a series of strategic expansions, relocations, and operational enhancements across its growing footprint. These initiatives reflect ENTA’s continued investment in improving patient access, modernizing clinical environments, and strengthening its presence in both established and emerging markets.

As part of this effort, ENTA recently consolidated its two Astoria, Queens offices into a newly developed 10,900 square-foot state-of-the-art clinical facility located at 28-18 31st Street, 2nd Floor, Astoria, NY. This investment reinforces ENTA’s strategy of strengthening key urban markets through thoughtful consolidation—bringing services together to improve efficiency, expand capacity, and deliver a more integrated care experience for patients.

ENTA will also relocate its Upper West Side office in June 2026 to a larger, more centrally located facility at 2431 Broadway. The new 8,900 square-foot office will support expanded services, improve patient flow, and accommodate continued growth in one of Manhattan’s busiest neighborhoods.

Both the Astoria and Upper West Side locations will serve as launch sites for ENTA’s newly developed walk-in care model, designed to further expand patient access and offer greater flexibility for patients seeking same-day, on-demand specialty care.

In Pennsylvania, ENTA continues to strengthen its suburban presence with the relocation of its Willow Grove office in the third quarter of 2026 to a newly upgraded 4,845 square-foot facility at 400 Horsham Road in Horsham, PA. The relocation will also introduce ENT services to the site, broadening the location’s clinical capabilities alongside its existing allergy and immunology offerings.

ENTA’s expansion efforts are also supported by a major technology transformation, with the organization set to implement the Epic electronic health record platform in November 2026. This transition will unify clinical and operational systems across the enterprise, enabling real-time access to patient information, improving coordination across care teams, and enhancing the overall patient and provider experience. In addition, ENTA is implementing Workday Financials and Procurement, with a targeted go-live date of July 1, 2026. This enterprise-wide initiative will modernize the organization’s financial and procurement operations, providing enhanced visibility, improved reporting capabilities, and more efficient management of purchasing and supplier relationships.

“These initiatives represent an important milestone in ENTA’s continued growth,” said Daniel Blum, Chief Executive Officer of ENTA. “As we continue to expand strategically across our markets, we remain focused on creating a more connected, accessible, and patient-centered model of specialty care. By investing in modern facilities and evolving how care is delivered, we are positioning ENTA to better serve our communities while supporting long-term growth across the organization.”

For more information about ENTA, to find a local office, or to schedule an appointment, please visit www.entandallergy.com or call 1-855-ENTA-DOC.

About the ENT & Allergy Associates Network:

ENT & Allergy Associates (ENTA) is the largest ENT, Allergy, and Audiology network in the country, with over 475 clinicians who practice in over 80 clinical locations throughout New York, New Jersey, Pennsylvania, and Texas. Each ENTA clinical office is comprised of world-class physicians who are specialists and sub-specialists in their respective fields, providing the highest level of expertise and care. With a wide range of services including Adult and Pediatric ENT & Allergy, Voice and Swallowing, Advanced Sinus and Skull Base Surgery, Facial Plastics and Reconstructive Surgery, Treatment of Disorders of the Inner Ear and Dizziness, Asthma-related services, Diagnostic Audiology, Hearing Aid Dispensing, Sleep and CT Services, ENTA is able to meet the needs of patients of all ages. ENTA is also affiliated with some of the most prestigious medical institutions in the world. Each year ENTA physicians are voted ‘Top Doctor’ by Castle Connolly, a true testament to the exceptional care and service they provide to their patients.

CONTACT: Jason Campbell ENT & Allergy Associates 914-984-2531 jcampbell@entandallergy.com 

Jakarta, Indonesia, May 28, 2026 (GLOBE NEWSWIRE) —

Held at the newly established AIMS Indonesia Office in central Jakarta

AIMS officially launched AIMS Indonesia on 25th May 2026, marking a major milestone in the company’s regional expansion and reinforcing its long-term commitment to Southeast Asia’s largest economy.

The Grand Opening celebrated a defining achievement for the company: securing the BAPPEBTI licence, the regulatory authorisation that formally permits AIMS to operate in Indonesia. With this approval, AIMS Indonesia is fully authorised to serve the Indonesian market with high standards of compliance, fund security, and institutional-grade trading infrastructure.

Held at the newly established AIMS Indonesia Office in central Jakarta, the event welcomed more than 300 guests, including industry leaders, strategic partners, clients, media representatives, and AIMS delegates from across the globe.

The evening featured a Lamborghini Huracán displayed beneath a custom-built LED tunnel, alongside an immersive brand showcase that reflected AIMS’ premium positioning and global ambitions.

A key highlight of the event was a corporate presentation tracing the growth of AIMS since its establishment in 2015, including landmark partnerships with Borussia Dortmund in 2022, the ASEAN Football Federation in 2023, Tottenham Hotspur in 2024, and Lamborghini in 2026.

“This is not merely an office opening — it is a declaration of our long-term commitment to Indonesia and to every trader who has placed their trust in us,” said Mr. Windy Alexandra, CEO of AIMS Indonesia. “Fund safety remains at the core of everything we do. Receiving our BAPPEBTI licence validates our approach and affirms that AIMS Indonesia is here to serve the market with integrity, transparency, and the highest standards of compliance.”

With a population exceeding 270 million, growing digital adoption, and rising interest in financial markets, Indonesia represents one of the region’s most important growth opportunities for AIMS.

The launch of AIMS Indonesia marks the beginning of a significant new chapter for the Group. Backed by a strong local leadership team, BAPPEBTI regulatory approval, and the global AIMS ecosystem, AIMS Indonesia is positioned to become a leading force in one of Southeast Asia’s most dynamic financial markets.

Windy Alexandra, CEO of AIMS Indonesia and his team

About AIMS

AIMS is a brand with an 11-year industry heritage and a trusted financial broker for institutional and individual traders worldwide. With a global presence spanning more than 21 countries and regions, the is renowned for its high-performance trading platforms, highly competitive spreads, and client-centric service philosophy, continuously driving development and innovation in the global trading industry.

Press Inquiries

Benson Low
media [at] aimsfx.com
https://aimsfx.com/

The Pediatric COVID Outcomes Study (PECOS) led by Roberta DeBiasi, MD, MS, chief of the division of Pediatric Infectious Diseases at Children’s National and Gina Montealegre Sanchez, MD, MS, pediatric rheumatologist at NIH’s National Institute of Allergy and Infectious Diseases (NIAID), provides crucial guidance for understanding pediatric COVID-19 outcomes.
The research teams behind these three papers examined overall symptom burden, behavioral health and cardiology outcomes in hundreds of children and adolescents, comparing those who had COVID-19 with those who did not.

“This study included mostly children with mild COVID-19 similar to what was seen during the pandemic period and results should be interpreted accordingly,” said study author and co-principal investigator, Dr. Montealegre Sanchez.

Long-COVID symptoms identified and tracked
As the first and largest study of its kind in the U.S. to publish longitudinal data, researchers reported on symptoms that children experienced in the first 12 months after enrollment in the study. They identified 20 symptoms more commonly reported in those who had COVID-19, including headaches, fatigue, forgetfulness, gastrointestinal issues, malaise and respiratory issues. Symptoms varied by age, with some appearing early and others persisting or emerging months later.

“This study helps us understand how post-COVID symptoms in children evolve over time, and importantly, across different age groups,” said Alexandra Yonts, MD, infectious diseases specialist at Children’s National and co-lead author of the study. “Since childhood is such a dynamic period of growth and development, tracking these symptoms at multiple time points and in children of many different ages is critical to know what the true long-term impacts of SARS-CoV-2 infection look like in the pediatric population.”

Physical health impacted, but mental health effects widespread
In another research project conducted with more than 800 youth who participated in the broader PECOS study, researchers found that children who had COVID-19 reported worse global health, reduced physical and cognitive functioning, and increased fatigue, pain and sleep disturbances. However, rates of anxiety and depression were similar between infected and uninfected children.

“The pandemic has affected all children’s mental health, not just those who were infected,” said research paper author Linda Herbert, PhD, director of Psychology Research and Clinical Services, Allergy and Immunology at Children’s National. “These findings highlight the broad impact of this experience on an entire generation.”

No evidence of heart damage in children
In reassuring news, a third prospective project found no evidence that COVID-19 causes long-term heart damage in children. Using advanced imaging, researchers observed no differences in cardiac function between infected and uninfected youth or even before and after infection. Children reporting symptoms such as chest pain or fatigue also had normal heart function.
“While some children experience these seemingly cardiac symptoms, our findings show these are not linked to underlying heart dysfunction,” said research paper author Michael He, MD, cardiology fellow at Children’s National.

A clearer path forward for care
Together, these findings help distinguish between the direct effects of COVID-19 infection and the broader impacts of the pandemic itself. The findings will help guide screening, clinical care and reassurance for families navigating post-COVID concerns.

Source: Crypto Insider

In honor of the 250th anniversary of U.S. independence, the Mint curated a list of 21 historic coins spanning our Nation’s history, from its founding in 1792 to the 21^st century. Following public input and expert recommendation, five Best of the Mint coins were selected for this special series: the 1916 Mercury Dime, the 1916 Standing Liberty Quarter Dollar, the 1916 Walking Liberty Half Dollar, the 1804 Silver Dollar, and the 1907 Saint-Gaudens High Relief $20 Gold Coin.

The Best of the Mint 1916 Mercury Dime Gold Coin and Silver Medal Set features a 24-karat one-tenth ounce fine gold coin and a one-ounce medal made of 99.9% fine silver. Pricing for this product is in accordance with the United States Mint pricing range table for gold coins.

Customers may sign up for a “Remind Me” alert for this set or view other Semiquincentennial Numismatic products.

1916 Mercury Dime 24K Gold Coin

The coin’s obverse (heads) depicts Liberty in profile facing left, wearing a winged cap symbolizing freedom of thought. Inscriptions are “LIBERTY,” “IN GOD WE TRUST,” and “1916.” To commemorate the Semiquincentennial of our Nation’s founding, the coin features a unique Liberty Bell privy mark with the numeral “250.” The coin’s reverse (tails) depicts a fasces (a bundle of rods) to symbolize strength through unity. The battle ax and the olive branch represent America’s military readiness and her desire for peace. Inscriptions are “UNITED STATES OF AMERICA,” “E PLURIBUS UNUM,” and “ONE DIME.”

1916 Mercury Dime – Inspired Silver Medal

Also known as the Winged Liberty Dime, the medal’s obverse features a design that spans from obverse to reverse and reflects the original coin’s period of circulation from 1916 through 1945. The design represents years of great change and upheaval for the United States, both domestically and abroad. Observing that the United States would enter two world wars during this period, Liberty is depicted in both defensive and offensive postures.

The medal’s reverse design extends to the reverse with rays emitting from Liberty’s sword, symbolic of hope at the end of conflict. The Great Depression is represented by the Hooverville shacks, and the swirling waves in the background represent the Dust Bowl. The inscription is “1916–1945.”

About the United States Mint

Congress created the United States Mint in 1792, and the Mint became part of the Department of the Treasury in 1873. As the Nation’s sole manufacturer of legal tender coinage, the Mint is responsible for producing circulating coinage for the Nation to conduct its trade and commerce. The Mint also produces numismatic products, including proof, uncirculated, and commemorative coins; Congressional Gold Medals; silver and bronze medals; and silver and gold bullion coins. Its numismatic programs are self-sustaining and operate at no cost to taxpayers.

Additional Resources

• Sign up to receive electronic product notifications, news releases, public statements, and our monthly educational newsletter, Lessons That Make Cents.
• Follow us on Facebook, X, and Instagram; visit and subscribe to our YouTube channel.

Source: Crypto Insider

Allschwil, Switzerland, May 28, 2026

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, awarded USD 13.3 million to Basilea to continue the development of Basilea’s novel oral antibiotic ceftibuten-ledaborbactam etzadroxil, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis.

David Veitch, Chief Executive Officer of Basilea, said: “Basilea is proud to be developing ceftibuten-ledaborbactam in partnership with BARDA. This funding helps us to further advance this novel antibiotic, including the preparation of the clinical phase 3 program. By advancing this promising candidate, we are potentially addressing the critical unmet need for the oral treatment of cUTIs caused by multidrug-resistant Gram-negative bacteria.”

After the current tranche of USD 13.3 million, a total of USD 25 million have been committed by BARDA. The contract^[1] could provide up to USD 133 million of additional non-dilutive funding.

About beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations

Many Gram-negative bacteria express enzymes such as extended spectrum beta-lactamases (ESBL) that confer resistance against commonly used antibiotics. Beta-lactamase inhibitors block these enzymes and restore the activity of beta-lactam antibiotics against initially resistant Gram-negative bacteria, therefore BL/BLI combinations are an important addition to the armamentarium for the treatment of infections caused by multidrug-resistant bacterial pathogens.

About ceftibuten-ledaborbactam etzadroxil

Ledaborbactam etzadroxil is the orally bioavailable prodrug of ledaborbactam, a novel broad-spectrum boronic acid beta-lactamase inhibitor, which is being developed in combination with ceftibuten, an oral cephalosporin antibiotic, which is approved in the US for the treatment of upper and lower respiratory tract infections and for urinary tract infections outside the US. In vitro and in vivo studies demonstrated that ledaborbactam etzadroxil restores the activity of ceftibuten against strains of Enterobacterales expressing Ambler class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and class A and D carbapenemases (KPC and OXA-48, respectively) as well as multidrug-resistant (MDR) Enterobacterales.^[2] Ceftibuten-ledaborbactam etzadroxil has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the US Food and Drug Administration (FDA) for cUTI and uncomplicated urinary tract infections. Ceftibuten-ledaborbactam etzadroxil is an investigational drug and is not yet approved in any country for commercial use.

About complicated urinary tract infections (cUTI)

Complicated UTIs, which include pyelonephritis (kidney infections), are defined as urinary tract infections ascending from the bladder accompanied by local and systemic signs and symptoms and are one of the most common bacterial infections in hospital and community settings. Increasing resistance of bacteria causing complicated urinary tract infections has led to limited availability of effective oral antibiotic treatment options.^[3] Currently, there are no approved oral beta-lactam or beta-lactam/beta-lactamase inhibitor combinations that are effective against Enterobacterales expressing Ambler class A ESBLs, class C cephalosporinases, and class A & D serine carbapenemases (KPC and OXA-48).

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

This ad hoc announcement can be downloaded from www.basilea.com.

References

1. This project has been funded in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50123C00050.
2. J. A. Karlowsky, M. G. Wise, M. A. Hackel et al. Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance Collection. Antimicrobial Agents and Chemotherapy 2022, Nov 15;66(11):e0093422
3. T. P. Lodise, T. Chopra, B. H. Nathanson et al. Epidemiology of Complicated Urinary Tract Infections due to Enterobacterales Among Adult Patients Presenting in Emergency Departments Across the United States. Open Forum Infectious Diseases 2022, Jun 24;9(7):ofac315.

Attachment

• Ad hoc release

With immediate effect, the Board has appointed Debrako BV, permanently represented by Mr. Koen De Brabander, as ad interim presiding member of the Management Committee. In this capacity, Koen De Brabander will lead the management team and serve as the Board’s primary interlocutor on matters of day-to-day management. The management team will ensure full continuity of operations and execution against the company’s strategic priorities.

Peter Mulroy, Chairman of the Board of Directors, commented: “On behalf of the entire Board, I want to thank Nicolas warmly for what he built at Banqup. He came in at a critical moment and drove a genuine transformation, delivering on the Belgian e-invoicing rollout and helping position us ahead of one of the most significant regulatory opportunities in our market. We wish him well. I have full confidence in Koen and the management team to carry that work forward with the focus and momentum our shareholders expect.”

Financial Calendar:
25 August 2026: Publication of the H1 2026 results (webcast)
13 November 2026: Publication of the Q3 2026 Business Update

Contact
Vincent Nagels
Investor Relations
Banqup Group
Investor.relations@banqup.com

About Banqup Group

Banqup Group delivers integrated cloud-based SaaS solutions to streamline business transactions across the
entire lifecycle, from e-invoicing and e-payments to tax reporting. Banqup, our solution for businesses, unifies
purchase-to-pay, order-to-cash, e-invoicing compliance, and e-payments into one secure platform, removing the
complexity of juggling disconnected tools. eFaktura World, our solution for governments, is a comprehensive
digital platform designed for tax administrations to implement e-invoicing and streamline both B2G and B2B tax
reporting flows. To learn more about Banqup Group and our solutions, please visit our website: Banqup Group

Cautionary note regarding forward-looking statements: The statements contained herein may include prospects, statements of future expectations, opinions, and other forward-looking statements in relation to the expected future performance of Banqup Group and the markets in which it is active. Such forward-looking statements are based on management’s current views and assumptions regarding future events. By nature, they involve known and unknown risks, uncertainties, and other factors that appear justified at the time at which they are made but may not turn out to be accurate. Actual results, performance or events may, therefore, differ materially from those expressed or implied in such forward-looking statements. Except as required by applicable law, Banqup Group does not undertake any obligation to update, clarify or correct any forward-looking statements contained in this press release in light of new information, future events or otherwise and disclaims any liability in respect hereto. The reader is cautioned not to place undue reliance on forward-looking statements.

Attachment

• 26-05-28 Banqup Press release